Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Determination of Enteric Coating Integrity – V 2.0

Posted on By

Analytical Method Development: SOP for Determination of Enteric Coating Integrity – V 2.0

Standard Operating Procedure for Determination of Enteric Coating Integrity in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/291/2025
Supersedes SOP/AMD/291/2022
Page No. Page 1 of 11
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To establish a validated procedure for evaluating the integrity of enteric coatings on solid oral dosage forms, ensuring the dosage unit resists disintegration in acidic

media and meets dissolution criteria in buffer media as per pharmacopeial and regulatory standards.

2. Scope

This SOP applies to the Analytical Method Development and Quality Control departments responsible for testing enteric-coated tablets or capsules during formulation development, stability studies, and batch release.

3. Responsibilities

  • Analytical Scientist: Designs and validates acid resistance and buffer dissolution methods.
  • QC Analyst: Conducts routine integrity testing and reports results.
  • QA Executive: Reviews data and ensures regulatory compliance.
See also  Analytical Method Development: SOP for GC-MS Method for Residual Solvents - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring accurate, validated, and compliant methods to verify enteric coating performance across batches.

5. Procedure

5.1 Apparatus

  • USP Dissolution Apparatus I (Basket) or II (Paddle)
  • Disintegration Tester (optional)
  • UV-Visible Spectrophotometer or HPLC

5.2 Acid Resistance Test

  1. Use 0.1N HCl as medium, 750 mL per vessel at 37 ± 0.5°C.
  2. Set apparatus: Paddle at 50 rpm or Basket at 100 rpm.
  3. Place 6 dosage units and run for 2 hours.
  4. Check for visual disintegration or drug release (NMT 10%).
  5. Collect sample at end of acid stage, filter, and analyze using UV or HPLC.

5.3 Buffer Dissolution Test

  1. Add 250 mL of pre-warmed phosphate buffer (pH 6.8) to each vessel to make total volume 1000 mL.
  2. Continue run as per dissolution specification (e.g., 45 or 60 minutes).
  3. Withdraw samples at predetermined time points (e.g., 15, 30, 45 min).
  4. Filter samples and measure absorbance at λmax or inject into HPLC.
See also  Analytical Method Development: UPLC Method Development and Optimization - V 2.0

5.4 Evaluation and Acceptance Criteria

  • Acid Stage: NMT 10% of drug should be released after 2 hours.
  • Buffer Stage: NLT 80% drug should be released within specified time (typically 45 minutes).

5.5 Validation Parameters

  1. Specificity: No interference in acid and buffer stage media.
  2. Linearity: r² ≥ 0.999 over 50%–150% range.
  3. Accuracy: Recovery 98%–102% in both stages.
  4. Precision: RSD ≤ 2% at each stage.
  5. Robustness: Evaluate at ±5 rpm and ±0.1 pH media variation.

6. Abbreviations

  • HCl: Hydrochloric Acid
  • UV: Ultraviolet
  • HPLC: High Performance Liquid Chromatography
  • RSD: Relative Standard Deviation

7. Documents

  1. Enteric Coating Integrity Test Log – Annexure-1
  2. Dissolution Profile Data – Annexure-2
  3. Validation Summary Report – Annexure-3

8. References

  • USP <711>: Dissolution
  • ICH Q2(R1): Validation of Analytical Procedures
  • FDA Guidance for Enteric-Coated Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Ritika Deshmukh Vishal Patil Sunita Reddy
Designation Dissolution Analyst QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Enteric Coating Integrity Test Log

Sample ID Acid Release (%) Buffer Release (%) Status
ECI-291-01 6.3% 91.2% Pass

Annexure-2: Dissolution Profile Data

Time (min) % Release
15 35%
30 68%
45 91%

Annexure-3: Validation Summary Report

The enteric coating integrity method was validated for specificity, precision, accuracy, and robustness. Results confirmed the integrity and performance of the enteric layer under simulated gastrointestinal conditions.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Updated buffer media conditions and validation acceptance criteria Annual Review Sunita Reddy
01/11/2022 1.0 Initial SOP Release New SOP QA Head
See also  Analytical Method Development: SOP for Method Verification for Pharmacopoeial Methods - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Elixir Department: SOP for Use of Mobile IPC Labs – V 2.0
Next Post: Why Process SOPs Must Reflect Validation Outcomes in GMP Operations

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version